The results of two studies indicate that combining antibodies against the programmed death 1 (PD-1) receptor with an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) improved treatment outcomes for patients with advanced melanoma, without a significant increase in adverse events.
General practitioners took longer to suspect a diagnosis of bladder or renal cancer in women compared with men, according to a recent study.
Patients who received a prescription for a lethal dose of secobarbital as part of a Death with Dignity program qualitatively described being grateful for the prescription, whether or not it was used, according to a recent study.
A high skeletal muscle density has been linked to a twofold prolonged survival in patients with metastatic renal cell carcinoma compared with patients with low muscle density, according to a new study.
Last week, the FDA announced that it would grant priority review to pertuzumab (Perjeta), as a neoadjuvant treatment for women with HER2-positive early-stage breast cancer.
Adolescent and young white men are at a more than 50% increased risk for death from melanoma than women of the same age, a new study has found. The researchers called the difference “alarming.”
A 6-month regimen of treatment with trastuzumab for HER2-positive breast cancer failed to show noninferiority with the standard 12-month treatment regimen after 3.5 years of follow-up in the open-label, randomized, phase III PHARE trial.
Researchers have developed and tested a nomogram that uses various factors and can predict risk of recurrence in patients with major salivary gland carcinoma.
The International Myeloma Working Group recently released new recommendations to aid physicians in the treatment of bone disease related to multiple myeloma.
Prophylactic use of the SSRI escitalopram decreased the occurrence of depression in patients with head and neck cancers by 50% and resulted in significantly improved quality of life for 3 months after drug cessation, according to the results of the PROTECT trial.